The Hematopathology and Diagnostic Challenges of Rare Lymphomas

[1]  R. Advani,et al.  Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial , 2019, The Lancet.

[2]  H. Kiyoi,et al.  Biology and management of primary effusion lymphoma. , 2018, Blood.

[3]  J. Cerhan,et al.  Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. , 2018, Blood.

[4]  M. Weichenthal,et al.  Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial , 2017, The Lancet.

[5]  O. Abdel-Wahab,et al.  Diagnosis and classification of hematologic malignancies on the basis of genetics. , 2017, Blood.

[6]  A. Feldman,et al.  DUSP22 AND TP63 REARRANGEMENTS PREDICT OUTCOME OF ALK‐NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA: A DANISH COHORT STUDY , 2017, Blood.

[7]  A. Kanate,et al.  Plasmablastic lymphoma versus plasmablastic myeloma: an ongoing diagnostic dilemma , 2017, Journal of Clinical Pathology.

[8]  L. Staudt,et al.  General Biomarker Recommendations for Lymphoma. , 2016, Journal of the National Cancer Institute.

[9]  Lauren B. Smith,et al.  Plasmablastic Lymphoma: A Review of Clinicopathologic Features and Differential Diagnosis. , 2016, Archives of pathology & laboratory medicine.

[10]  Lauren B. Smith,et al.  Reed-Sternberg-Like Cells in Non-Hodgkin Lymphomas. , 2015, Archives of pathology & laboratory medicine.

[11]  H. Abel,et al.  T-cell clonality assessment by next-generation sequencing improves detection sensitivity in mycosis fungoides. , 2015, Journal of the American Academy of Dermatology.

[12]  L. Hynan,et al.  Defining early mycosis fungoides: validation of a diagnostic algorithm proposed by the International Society for Cutaneous Lymphomas , 2015, Journal of cutaneous pathology.

[13]  J. Castillo,et al.  The biology and treatment of plasmablastic lymphoma. , 2015, Blood.

[14]  R. Bergman,et al.  T-Cell Receptor Gene Rearrangement Studies Using the GeneScan Technique as an Adjunct to the Histopathological Diagnosis of Mycosis Fungoides , 2015, The American Journal of dermatopathology.

[15]  R. Advani,et al.  Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. , 2015, Blood.

[16]  K. Blum.  CD30: seeing is not always believing. , 2015, Blood.

[17]  R. Gascoyne,et al.  CD30 expression in de novo diffuse large B‐cell lymphoma: a population‐based study from British Columbia , 2014, British journal of haematology.

[18]  R. Advani,et al.  Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  W. Wilson,et al.  ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. , 2014, Blood.

[20]  K. Kayasut,et al.  Interobserver variation in classifying lymphomas among hematopathologists , 2014, Diagnostic Pathology.

[21]  G. Verhoef,et al.  Clinicopathologic Comparison of Plasmablastic Lymphoma in HIV-positive, Immunocompetent, and Posttransplant Patients: Single-center Series of 25 Cases and Meta-analysis of 277 Reported Cases , 2014, The American journal of surgical pathology.

[22]  S. Horwitz,et al.  Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers. , 2014, Journal of the American Academy of Dermatology.

[23]  D. Weisenburger,et al.  Targeting CD30 in Malignant Tissues: Challenges in Detection and Clinical Applications , 2013, Pathobiology.

[24]  A. Chadburn.  Immunodeficiency-associated lymphoid proliferations (ALPS, HIV, and KSHV/HHV8). , 2013, Seminars in diagnostic pathology.

[25]  W. Choi,et al.  CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. , 2013, Blood.

[26]  G. Heinze,et al.  Aberrant T-cell antigen expression in classical Hodgkin lymphoma is associated with decreased event-free survival and overall survival. , 2013, Blood.

[27]  J. Said,et al.  KSHV/HHV8-negative Effusion-based Lymphoma, a Distinct Entity Associated With Fluid Overload States , 2013, The American journal of surgical pathology.

[28]  L. Medeiros,et al.  Extracavitary/solid variant of primary effusion lymphoma. , 2012, Annals of diagnostic pathology.

[29]  P. Senter,et al.  The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma , 2012, Nature Biotechnology.

[30]  Scott E Smith,et al.  Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  B. Nathwani,et al.  Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project. , 2011, Blood.

[32]  S. Swerdlow,et al.  CD30 Expression and Proliferative Fraction in Nontransformed Mycosis Fungoides , 2009, The American journal of surgical pathology.

[33]  Stefano A Pileri,et al.  ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. , 2008, Blood.

[34]  I. Zalaudek,et al.  Regarding the algorithm for the diagnosis of early mycosis fungoides proposed by the International Society for Cutaneous Lymphomas: suggestions from routine histopathology practice , 2008, Journal of cutaneous pathology.

[35]  L. Thomas,et al.  Transformed mycosis fungoides: clinicopathological features and outcome , 2007, The British journal of dermatology.

[36]  S. Pileri,et al.  Rare expression of T-cell markers in classical Hodgkin's lymphoma , 2005, Modern Pathology.

[37]  Nicola Pimpinelli,et al.  Defining early mycosis fungoides. , 2005, Journal of the American Academy of Dermatology.

[38]  P. Gaulard,et al.  Mediastinal Gray Zone Lymphoma: The Missing Link Between Classic Hodgkin's Lymphoma and Mediastinal Large B-Cell Lymphoma , 2005, The American journal of surgical pathology.

[39]  J. Forteza,et al.  Large B‐cell lymphoma with Hodgkin's features , 2005, Histopathology.

[40]  D. Huhn,et al.  Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. , 1997, Blood.

[41]  M. Nasu,et al.  Clinicopathological features of adult T-cell leukemia with CD30 antigen expression. , 1994, Leukemia & lymphoma.

[42]  D N Shapiro,et al.  Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. , 1994, Science.

[43]  W. Wilson,et al.  Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach? , 2015, Blood.